VISEN Pharmaceuticals (HKG:2561)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
33.38
-0.18 (-0.54%)
At close: Feb 13, 2026
Market Cap3.51B
Revenue (ttm)921.55K
Net Income-237.56M
EPS-2.45
Shares Out105.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,500
Average Volume31,230
Open33.30
Previous Close33.56
Day's Range32.70 - 34.46
52-Week Range29.06 - 69.15
Betan/a
RSI44.85
Earnings DateApr 30, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy f... [Read more]

Sector Healthcare
Founded 2018
Employees 54
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2561
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements